Health Condition 1: E169- Disorder of pancreatic internal secretion, unspecified
Conditions
Interventions
Intervention1: Empagliflozin with Standerd of Care: Tablet Empagliflozin 10mg Once a day for three Months
Intervention2: Dapagliflozin with Standard of Care: Tablet Dapagliflozin 5mg once a day for th
Sponsors
Shoaib Ahmad
Eligibility
Inclusion criteria
Inclusion criteria: Patients more than 18 years of either gender Patients diagnosed with Prediabetes Fasting plasma glucose 100 to 125mg per dl or HbA1c 5.7 to 6.4 percent Patient willing to give informed consent
Exclusion criteria
Exclusion criteria: Patients with Uncontrolled Type 2 Diabetes Patients with eGFR less than 60ml per min per 1.73 meter square Patients with Cardiovascular Event in Past 6 Months Patients with Recurrent Urinary Tract Infection or genital mycotic infection Pregnant or Lactating Women Patients Taking Glucose Lowering drugs in Past 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in HbA1c from baseline to 6 monthsTimepoint: Mean change in HbA1c from baseline to 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Achieving Normoglycemia Changes in BMI waist circumference body composition change in lipid profile change in HOMA IR index incidence of ADRsTimepoint: over 6 months | — |
Countries
India
Contacts
Public ContactFarida Ahmad
Jawaharlal Nehru Medical College Aligarh Muslim University
Outcome results
None listed